Founded in 2007, Plaxgen is an early stage nanobiotechnology company focused on developing an innovative technology to discover effective therapeutics to treat a broad spectrum of plaque-related diseases including Alzheimer’s Disease (AD) and atherosclerosis. Plaxgen’s proprietary and patent pending “Plaque Array” platform was developed for illuminating and detecting growth/amplification of plaques that are related to the origin and progression of AD and atherosclerosis. We exploit our Plaque Array platform both to accelerate early stage drug discovery and non-invasively diagnose AD and atherosclerosis. Plaxgen has strong IP portfolios to protect in vitro plaque assembly methods and its Plaque Array platform.